Internal and Emergency Medicine

, Volume 13, Issue 2, pp 191–197 | Cite as

Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey

  • Chao-Feng Chang
  • Yu-Chen Tseng
  • Hsin-Hung Huang
  • Yu-Lueng Shih
  • Tsai-Yuan Hsieh
  • Hsuan-Hwai Lin
IM - ORIGINAL
First Online:
Received:
Accepted:

Abstract

Pancreatic cancer is difficult to diagnose in an early stage, and has the highest mortality of all types of cancer. Obesity, high body mass index, and increased abdominal girth are established risk factors. Some studies have postulated that there is a correlation between organ steatosis and pancreatic cancer. This study aims to explore whether nonalcoholic fatty liver disease (NAFLD) is a risk factor and a prognostic factor for pancreatic cancer. The study enrolled 557 patients (143 with and 414 without pancreatic cancer) who were diagnosed between January 2009 and December 2013. We reviewed the abdominal computed tomographic scans of the patients to confirm the diagnosis of NAFLD. Clinical parameters, laboratory data, and personal information were analyzed. NAFLD is an independent risk factor for pancreatic cancer according to adjusted multivariate logistic regression analysis (OR 2.63, 95% CI 1.24–5.58, p = 0.011). The Kaplan–Meier survival curve reveals that patients without NAFLD have longer survival than patients with NAFLD (p = 0.005, log-rank test). NAFLD is positively correlated with pancreatic cancer, a result suggesting that NAFLD may increase the incidence and risk of pancreatic cancer. Patients with pancreatic cancer and NAFLD have poorer overall survival than patients without NAFLD, perhaps, because dysregulated cytokine status leads to progression of pancreatic cancer. NAFLD may be a prognostic factor for pancreatic cancer.

Keywords

Fatty liver Pancreatic cancer Abdominal fat Computed tomography 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

The authors thank the Cancer Registry Group of Tri-Service General Hospital for the clinical data support. This study was supported by the Research Fund of the Tri-Service General Hospital (TSGH-C105-060).

Compliance with ethical standards

Conflict of interest

There was no conflict of interest.

Statement of human and animal rights

This study was reviewed and approved by the Institutional Review Board of the Tri-Service General Hospital (IRB:1-105-05-155).

Informed consent

This study was granted exemption from informed consent.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30CrossRefPubMedGoogle Scholar
  2. 2.
    Lowenfels AB, Maisonneuve P (2004) Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34(5):238–244CrossRefPubMedGoogle Scholar
  3. 3.
    Shaib Y, Davila J, El-Serag H (2006) The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24(1):87–94CrossRefPubMedGoogle Scholar
  4. 4.
    Bracci PM (2012) Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog 51(1):53–63CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Food N (2007) Physical activity, and the prevention of cancer: a global perspective. Washington, DCGoogle Scholar
  6. 6.
    Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169(5):1505–1522CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Włodarek D, Jerzy Podleśny JS (2007) Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Roczniki Państwowego Zakładu 58(1):129Google Scholar
  8. 8.
    Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A (2012) The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56(4):952–964CrossRefPubMedGoogle Scholar
  9. 9.
    Machado M, Cortez-Pinto H (2006) Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 9(5):637–642CrossRefPubMedGoogle Scholar
  10. 10.
    Pitt HA (2007) Hepato-pancreato-biliary fat: the good, the bad and the ugly. HPB 9(2):92–97CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Targher G, Rossi A, Zamboni G, Fantin F, Antonioli A, Corzato F et al (2012) Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J Endocrinol Investig 35(8):748Google Scholar
  12. 12.
    Smits MM, van Geenen EJ (2011) The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 8(3):169–177CrossRefPubMedGoogle Scholar
  13. 13.
    Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R et al (2009) Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg 208(5):989–994CrossRefPubMedGoogle Scholar
  14. 14.
    Sanna C, Rosso C, Marietti M, Bugianesi E (2016) Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci 17(5):717CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Saba L, di Martino M, Bosco S, del Monte M, de Cecco CN, Lombardo V et al (2015) MDCT classification of steatotic liver: a multicentric analysis. Eur J Gastroenterol Hepatol 27(3):290–297CrossRefPubMedGoogle Scholar
  16. 16.
    Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ et al (2010) Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol 194(3):623–628CrossRefPubMedGoogle Scholar
  17. 17.
    Park YS, Park SH, Lee SS, Kim DY, Shin YM, Lee W et al (2011) Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. Radiology 258(3):760–766CrossRefPubMedGoogle Scholar
  18. 18.
    Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML et al (2009) Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301(24):2553–2562CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Balentine CJ, Enriquez J, Fisher W, Hodges S, Bansal V, Sansgiry S et al (2010) Intra-abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg 14(11):1832–1837CrossRefPubMedGoogle Scholar
  20. 20.
    McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, De Andrade M et al (2010) Obesity adversely affects survival in pancreatic cancer patients. Cancer 116(21):5054–5062CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Olson SH, Chou JF, Ludwig E, O’Reilly E, Allen PJ, Jarnagin WR et al (2010) Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer 127(10):2412–2419CrossRefPubMedGoogle Scholar
  22. 22.
    Fearon KC, Baracos VE (2010) Cachexia in pancreatic cancer: new treatment options and measures of success. HPB 12(5):323–324CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    De González AB, Spencer EA, Bueno-de-Mesquita HB, Roddam A, Stolzenberg-Solomon R, Halkjær J et al (2006) Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 15(5):879–885CrossRefPubMedGoogle Scholar
  24. 24.
    van Geenen E-JM, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ (2010) Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 39(8):1185–1190CrossRefPubMedGoogle Scholar
  25. 25.
    Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A (2016) Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 11(1):3–10CrossRefPubMedGoogle Scholar
  26. 26.
    Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22(4):625–638CrossRefPubMedGoogle Scholar
  27. 27.
    Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92(18):1472–1489CrossRefPubMedGoogle Scholar
  28. 28.
    Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W, Kasuga M (2002) Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 24(1):42–46CrossRefPubMedGoogle Scholar
  29. 29.
    Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M (1995) Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55(10):2007–2011PubMedGoogle Scholar
  30. 30.
    Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN (2008) FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29(6):1096–1107CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T (2010) Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol 16(15):1854–1858CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Muniraj T, Chari ST (2012) Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol 58(4):331PubMedPubMedCentralGoogle Scholar
  33. 33.
    Li D (2012) Diabetes and pancreatic cancer. Mol Carcinog 51(1):64–74CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Salpea KD, Humphries SE (2010) Telomere length in atherosclerosis and diabetes. Atherosclerosis 209(1):35–38CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD et al (2003) Regulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163(3):1001–1011CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Zeng H, Datta K, Neid M, Li J, Parangi S, Mukhopadhyay D (2003) Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 302(1):46–55CrossRefPubMedGoogle Scholar
  37. 37.
    Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J et al (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294(22):2872–2878CrossRefPubMedGoogle Scholar
  38. 38.
    Iodice S, Gandini S, Maisonneuve P, Lowenfels AB (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393(4):535–545CrossRefPubMedGoogle Scholar
  39. 39.
    Nakamura K, Nagata C, Wada K, Tamai Y, Tsuji M, Takatsuka N et al (2011) Cigarette smoking and other lifestyle factors in relation to the risk of pancreatic cancer death: a prospective cohort study in Japan. Jpn J Clin Oncol 41(2):225–231CrossRefPubMedGoogle Scholar
  40. 40.
    Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar H-J (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388–2394CrossRefPubMedGoogle Scholar
  41. 41.
    Blais L, Desgagné A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160(15):2363–2368CrossRefPubMedGoogle Scholar
  42. 42.
    Simon MS, Desai P, Wallace R, Wu C, Howard BV, Martin LW et al (2016) Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. Cancer Causes Control 27(3):415–423CrossRefPubMedGoogle Scholar
  43. 43.
    Shimoyama S (2011) Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 67(4):729–739CrossRefPubMedGoogle Scholar
  44. 44.
    Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9(5):259–267CrossRefPubMedGoogle Scholar
  45. 45.
    Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59(17):4356–4362PubMedGoogle Scholar
  46. 46.
    Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ (2004) Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96(7):524–528CrossRefPubMedGoogle Scholar
  47. 47.
    Zhang Y-P, Wan Y-D, Sun Y-L, Li J (2015) Zhu R-T. A meta-analysis of observational studies. Sci Rep, Aspirin might reduce the incidence of pancreatic cancer, p 5Google Scholar

Copyright information

© SIMI 2017

Authors and Affiliations

  • Chao-Feng Chang
    • 1
  • Yu-Chen Tseng
    • 1
  • Hsin-Hung Huang
    • 1
  • Yu-Lueng Shih
    • 1
  • Tsai-Yuan Hsieh
    • 1
  • Hsuan-Hwai Lin
    • 1
  1. 1.Division of Gastroenterology, Department of Internal MedicineTri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan

Personalised recommendations